Sermorelin & GHRP-2 & GHRP-6 vs Retatrutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Sermorelin & GHRP-2 & GHRP-6
A powerful tri-blend combining Sermorelin (a GHRH analog) with two growth hormone releasing peptides. This combination produces significantly greater GH release than any single peptide, with studies showing up to 54-fold increases in pulsatile GH secretion.
Full details →Retatrutide
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials showed unprecedented weight loss of up to 24% at 48 weeks, making it potentially the most effective obesity treatment studied.
Full details →Side-by-Side Comparison
| Aspect | Sermorelin & GHRP-2 & GHRP-6 | Retatrutide |
|---|---|---|
| Mechanism | Sermorelin stimulates the pituitary via GHRH receptors, while GHRP-2 and GHRP-6 act as ghrelin mimetics on different receptor subtypes. The combination creates synergistic GH release through multiple complementary pathways. GHRP-6 also strongly stimulates appetite. | Triple receptor activation provides complementary metabolic effects: GLP-1 and GIP reduce appetite and improve insulin sensitivity, while glucagon receptor activation increases energy expenditure and promotes hepatic fat oxidation. |
| Typical Dosage | Typical protocols: Sermorelin 100-300mcg, GHRP-2 100-300mcg, GHRP-6 100-300mcg. Often administered 2-3 times daily, 30 minutes before meals or at bedtime. | Clinical trials used doses from 1mg to 12mg weekly. Optimal dosing still being determined in ongoing Phase 3 trials. |
| Administration | Subcutaneous injection. Best administered fasted or before sleep to maximize natural GH cycle. The three peptides can be mixed together or administered separately. | Subcutaneous injection once weekly. Currently only available through clinical trials - not yet FDA approved. |
| Side Effects | Increased hunger (especially from GHRP-6), water retention, facial flushing, nausea, tingling, potential increases in cortisol and prolactin levels. | Similar GI effects to other incretin-based therapies: nausea, diarrhea, vomiting, constipation. Dose-dependent severity. |
| Best For |
What They Have in Common
Both Sermorelin & GHRP-2 & GHRP-6 and Retatrutide are commonly used for: